<p>The recent article by Sharma et al., “ABO Blood Group as a Potential Risk Factor for Allergic Rhinitis: A Case Control Study,” offers an intriguing hypothesis linking ABO blood groups with susceptibility to allergic rhinitis (AR). While the findings are clinically relevant, several methodological limitations temper their interpretability. The selection of controls from hospital outpatients, rather than community-based populations, may have introduced selection bias. Additionally, important confounding variables such as exposure to allergens, smoking, air pollution, and socioeconomic determinants were not adequately addressed, raising concerns about residual confounding. Statistical analysis relied on chi-square tests without reporting odds ratios or confidence intervals, limiting insights into effect size and clinical applicability. Multiple subgroup analyses, including AR severity across blood groups and Rh phenotypes, were performed without correction for multiple comparisons, increasing the likelihood of false positive results. The interpretation of Rh phenotype associations is further complicated by the lack of population-based prevalence data. Moreover, the small sample size, particularly in the AB blood group, reduces statistical power and reliability of conclusions. Finally, the case control design precludes causal inference. Larger, community-based, and methodologically rigorous studies are warranted before ABO blood grouping can be considered a reliable biomarker for AR susceptibility or severity.</p>